Apple (AAPL) stocks have declined by more than 20 percent this year. Concerns about sluggish profit growth and a faltering economy have severely impacted the FAANGs (Facebook -now Meta, Apple, Amazon, & Google) of Big Tech and other momentum stocks. In this dismal market for the Nasdaq and S&P 500, however, numerous blue-chip healthcare firms have shown substantial gains.
Merck (MRK) and biotechnology leader Amgen (AMGN) are among Dow’s best performers. McKesson (MCK), Vertex (VRTX), Eli Lilly (LLY), and Cigna (CI) are S&P 500 winners as well. Bristol-Myers Squibb (BMY), Eli Lilly (LLY), and Humana (HUM) are all near record highs.
Notably, these are not the large Covid vaccination supplies either. Pfizer (PFE), BioNTech (BNTX), Moderna (MRNA), and Novavax (NVAX) have all decelerated in 2022 after seeing significant price increases in 2021. Gilead (GILD) and Regeneron (REGN) are also in the red this year as antiviral medicine manufacturers.
The present economic cycle is more influential than the epidemic in driving the big rise of other healthcare firms. During turbulent times, health care equities frequently perform well. Even during a recession, they are viewed as reliable enterprises that deliver products and services that consumers require.
In addition, a number of market leaders in the healthcare industry provide substantial dividends and are relatively inexpensive relative to the rest of the market.
In a recent analysis, UBS Global Wealth Management’s chief investment officer for the Americas, Solita Marcelli, stated that healthcare is trading at an appealing valuation for a late-cycle environment.
Since 2003, she said, global healthcare companies have tended to outperform the overall market by more than 6% when the manufacturing sector is in decline. (The May reading of the ISM Manufacturing Index was the second-lowest since May 2020.)
An economist and portfolio strategist at New York Life Investments, Lauren Goodwin, noted in a study that “as long as economic growth remains in flux,” investors should continue with quality equities with a “defensive bent.” In addition to healthcare, she mentioned utilities and real estate as two more sectors noted for their high payouts.
An increase in mergers could also benefit the healthcare industry. This year, Pfizer, Bristol-Myers Squibb, and GSK (previously Glaxo Smith Kline) announced multi-billion-dollar agreements.
There are inherent hazards. Depending on the outcome of the midterm elections, regulators and legislators may scrutinize healthcare corporations more closely. If Republicans win control of the House and Senate, the future of the Affordable Care Act (Obamacare) and its impact on prescription pricing could be called into question.
However, as long as the Federal Reserve continues to rapidly raise interest rates and investors remain concerned about inflation, healthcare stocks may continue to do well regardless of what occurs on Capitol Hill.
The stock market has experienced a flight to quality, according to Edward Campbell, co-head of the multi-asset team at PGIM Quantitative Solutions. “I’m not surprised to see more classically defensive sectors like healthcare continue to do well.”
Fears of a recession are mounting as a result of rate hikes, soaring oil and gas prices, and housing market problems. However, one of the most vital aspects of the US economy, the job market, remains robust.
In the middle of the Great Resignation, workers are in the proverbial driver’s seat, commanding substantial compensation as firms struggle to hire staff. But could the job market be about to take a turn for the worse as well?
Friday, the government releases June payroll data. The statistics will conclude a week filled with employment-related headlines, including weekly unemployment figures, monthly reports from payroll processor ADP regarding private-sector jobs, and the government’s job openings and labor turnover (JOLTS) survey.
Economists predict that 295,000 new jobs were created in June. This is still a strong number, although it is lower than the 390,000 jobs added in May and the revised increase of 436,000 jobs in April.
The unemployment rate is projected to remain stable at 3.6%, but it is likely to gradually begin to rise. According to forecasts made at the Fed’s most recent meeting earlier this month, members of the central bank anticipate that the unemployment rate would end this year at 3.7%, rise to 3.9% in 2023 and reach 4.1% in 2024.
Obviously, this is still historically low. As pay growth begins to stall, though, there are concerns that American workers won’t be able to keep up with soaring inflation. The average hourly wage increased by 5.2% year-over-year in May, down from 5.5% in April.
Economists, investors, and job searchers will closely monitor the June data to determine if wage growth has deteriorated further.
TSMC to Continue Pushing in 2023
Still has momentum.
We still issue a buy rating on the Taiwan Semiconductor Manufacturing Company (NYSE: TSM). Our optimistic outlook on TSMC is based on our belief that the firm is better positioned to outperform now, as the semiconductor industry slowly but steadily improves and the company accounts for lower demand in FY2023. TSMC’s fourth-quarter earnings reports were mixed; the company beat profitability projections but fell short on sales. Despite this, the stock climbed roughly 5% when earnings were released. We believe TSM is attempting to counteract reduced end-market demand and inventory corrections, which have hurt sales and lowered forecasts for the upcoming quarter. It is likely that a bottom in TSM and the semi-space in 1H23, followed by a significant recovery in the year’s second half.
We feel that TSM’s stock is a good entry place before the semi-space rebounds. Since our last post on TSMC in late October, the company has already gained 41%, surpassing the SOX index, which has gained only 21%. The graph below depicts our rating history for TSMC.
We urge that investors disregard the market hype surrounding fears of a Chinese invasion of Taiwan and instead focus on the company’s industry-first approach. We believe that TSMC is best positioned to benefit from chip demand once the semiconductor market recovers. Furthermore, we anticipate the company will have the additional power to raise ASP in the second half of 2023. We recommend that investors purchase the stock at current levels in order to benefit from TSM’s rising growth trend in 2023.
The leading pure foundry space allows for ASP gains.
We favor TSMC’s position in the foundry industry, with a 60% market share in 4Q22, and expect it to boost ASP on advanced nodes. We predict TSMC’s market share will expand significantly in 2022 as a result of the increased manufacture of smaller, more sophisticated 5nm wafers. Nanometer size is at the heart of technical developments in the semiconductor industry and, by extension, the world. To be more specific, nanoscale size refers to the distance between transistors on a chip; the smaller the chip, the more advanced and high-performing it is. Our positive outlook on TSM is predicated on our expectation that the company’s growth would be driven by increased adoption of advanced nodes, which are gradually accounting for a larger portion of TSMC’s revenue by technology. TSM has also begun the manufacture of 3nm processors for Apple (AAPL), sustaining Moore’s Law and looking ahead to next-generation technologies.
We anticipate that the rising global adoption of advanced nodes to meet the surging demand for semiconductors will fuel TSMC’s medium- to long-term growth. As a result, we anticipate that TSMC’s position will allow it to improve ASP on advanced nodes in 2H23, owing to the fact that it retains big semi-players as top clients, including Nvidia (NVDA), Advanced Micro Devices (AMD), and AAPL, among others.
Headwinds still persist
TSMC is not immune to the demand slowdown caused by macroeconomic headwinds, as seen by a dip in 1H23 followed by a fast recovery in 2H23. In Thursday’s results call, TSMC CEO C.C. Wei clarified, stating he anticipates 2023 to be a “slight growth year.” We expect TSMC will face inventory corrections in 1H23 as a result of the deteriorating chip-demand environment. We estimate CAPEX reduction in TSMC during 2023, largely as major client AAPL forecasts reduced demand despite weaker consumer spending. TSMC management warned that revenue would fall by roughly 5% in 1Q23, and that annual spending would be reduced. TSMC announced a CAPEX of $36.3B in 2022 and expects CAPEX to be $32-36B in 2023. We are not concerned by TSMC’s lower 1Q23 prediction because we believe the firm is de-risking guidance due to the challenging macro environment.
Despite the macroeconomic challenges, we expect TSMC to continue growing its foundry operations outside of Taiwan in order to mitigate the risks of geographically concentrating manufacturing on the disputed Island. We believe TSMC will play a larger role in the global shift to manufacturing chips in the United States after the CHIPS Act is implemented in 2022. The business intends to more than increase its investment in US foundries to $40 billion by 2026, establishing the US as a hub for advanced chip manufacturing. We estimate that it will take three to four years for US semiconductor companies Intel (INTC) and TSMC to meaningfully produce chips on US territory. Nonetheless, we anticipate that TSMC’s US fabs will be a long-term growth driver.
We predict TSMC stock to rise in the second half of 2019 as the semiconductor sector recovers from a 15-month slump. We anticipate that product introductions and expanded manufacturing of 5nm wafers will help the semiconductor industry recover.
We feel TSMC is a value investment since it is selling at a discount to its peer group average. The company is trading at 14.4x C2023 P/E, compared to the peer group average of 21.9x. The company is currently selling at 0.2x EV/C2023 Sales, compared to the peer group average of 4.8x. We believe TSMC stock offers an appealing entry point at current levels, and that investors who purchase the stock now will be well rewarded in 2023.
What should be done with the stock?
We remain optimistic about TSMC. We believe the stock is reacting to lower chip demand in 2023. While we expect the stock to remain volatile in 1H23 as the semiconductor space bottoms, we believe TSMC will benefit from demand tailwinds as the semi-space recovers in 2H23. We also anticipate that TSMC’s growth will be fueled by higher 5nm production and the company’s capacity to boost ASP on advanced nodes in 2H23. We feel the stock offers a good entry point at the current price and propose that investors acquire it.
For More Financial News, Click Here.
Solana is Coming Back to Life With a Massive Surge
It’s a true comeback: the triumphant return of Solana that many experts and industry insiders had written off after the bankruptcy of Sam Bankman-Fried’s FTX on November 11.
They predicted that SOL would not be able to withstand the earthquake symbolized by the collapse of the FTX cryptocurrency exchange and its sister company Alameda Research, a hedge fund that also serves as a trading platform for institutional investors.
In the crypto world, FTX and Alameda were the major corporations representing the Bankman-Fried crypto empire, abbreviated SBF.
Solana did, in fact, have intimate ties to Bankman-Fried. Sol, also known as “Sam coin,” is a token produced by the Solana Blockchain that enables the development of decentralized finance or DeFi projects that provide financial services such as loans, mortgages, financial products, and so on.
The coin is linked to an on-chain crypto exchange dubbed project Serum, which was founded by Bankman-Fried, who resigned on November 11 when his enterprise declared bankruptcy.
Serum is one of the infrastructure’s pillars, as it is the protocol and ecosystem that enables Solana DeFi’s fast speed and low transaction cost. It provides an on-chain central limit order book and matching engine, allowing institutional and retail investors to share liquidity and use strong trading features.
It allows developers the freedom to create trading applications without limitations, as it is not tied to any specific assets. This allows them to utilize Serum’s liquidity and ecosystem advantages in their trading application.
As if to prove Cassandra correct, Sol prices plunged by 73% between the onset of FTX’s issues on November 6 and December 31.
They finished the year at $9.96, down from $32.72 on November 5.
SOL has increased by 79%.
However, as quickly as they fell, so did the prices of Sol. According to monitoring firm CoinGecko, they are up 79% in the last seven days. Sol is currently knocking on the doors of the top ten cryptocurrencies in terms of market value. Before the club’s demise, the token belonged to it.
Prices are currently trading at $23.39, a 134% increase from the beginning of the year.
After a statement of support from Vitalik Buterin, one of the most important voices in the crypto world, sentiment toward Solana shifted.
“Some clever people tell me there is a sincere brilliant developer community in Solana, and now that the nasty opportunistic money people have been washed out, the chain has a bright future,” Buterin, one of the co-founders of Ethereum, the most powerful crypto platform, wrote on Twitter on December 29.
“Hard for me to know from the outside,” he said, “but I hope the neighborhood gets a fair shot to grow.”
According to numerous industry sources, the resurrection of SOL is also attributable to an increase in demand for decentralized financial projects. The Solana blockchain enables developers to create decentralized apps, or dApps, at a low cost and provides fast transaction execution.
Its scalability, speed, and affordability make it an appealing alternative for DeFi initiatives that require significant volumes of transactions to be processed rapidly and at a cheap cost.
“While traders are cheering the return of Bitcoin (back over $21,000), and Ethereum (back over $1,550), #Solana is the real star as the weekend begins,” said Santiment, an on-chain analytics business. “$SOL has gained +22% in the last two hours alone, fuelled by liquidated shorts.”
According to Santiment, the significant comeback in Sol prices is the result of a “short squeeze,” which is a fast increase in the price of an asset caused by investors who bet against the product, being forced to purchase it in order to limit their losses.
For More Financial News, Click Here.
Is Alibaba Now Poised to Rally?
After reaching record lows not seen since 2016, 2022 was merciless for Alibaba Group Holding (NYSE: BABA). This comes as no surprise given all of the recent China-related news. A zero-COVID policy has stifled output and demand, while antitrust laws from the ruling party have targeted its tech companies. The continued supply chain and labor constraints haven’t helped matters either. Was 2022 always a difficult year with such headwinds?
Maybe, but things are starting to turn around, and it appears that the bulls have returned. Major tailwinds are expected to carry Alibaba into 2023. Let’s look at a few of them.
For openers, analysts have identified numerous stocks as poised for a comeback bounce in the coming year. Alibaba is one of the most recent example. On Monday, Morgan Stanley named the e-commerce behemoth their favorite in the tech sector. According to Gary Yu and his team, investors have “underappreciated Alibaba’s leverage to a Chinese consumption rebound.” This is mostly owing to its retail success in areas such as consumer products.
Yu also anticipates an improvement in China’s regulatory environment, which will go a long way toward reversing the selling pressure that has brought shares down as much as 80% from their 2020 highs. But it isn’t all. Founder Jack Ma recently announced his intention to step down as CEO and pass over the reigns to someone else.
With his name now being disassociated with Alibaba, one more risk and possible headwind has been removed.
Along with the bullish outlook, Morgan Stanley reiterated its Outperform rating and set a $150 price objective for Alibaba shares. This indicates a 30% upside from current levels based on where they closed on Wednesday. Shares are already up almost 100% from their lows in October, so this outlook, simply adds gasoline to the belief that a significant recovery rally is in the works.
Additional tailwinds exist in the shape of the zero-COVID policy being reversed, which will finally allow the Chinese economy to recuperate after living in constant dread of a lockdown. This comes after widespread rallies caused the government to cave, which is unusual in China.
Alibaba’s Risk Factors
There are risks, the most visible of which are geopolitical tensions. When compared to a decade ago, the United States and China are no longer on good terms. The conflict in Ukraine and escalating tensions with Taiwan have not helped the relationship.
This has filtered down to corporations, with the United States refusing to transfer semiconductor chips to China for fear that they may be used against them in the future. Chinese retaliation is not ruled out and would almost certainly aggravate the situation.
Furthermore, the delisting risk that has dogged Alibaba and its counterparts in recent years has not materialized as many bears predicted. It still exists, but the longer Alibaba remains on the good side of US auditors, the more likely its shares will become a permanent fixture on the New York Stock Exchange.
Indeed, there was news on this front as recently as the last week of December, when it was reported that numerous US-listed Chinese companies had abandoned intentions to list in Hong Kong. This approach was positioned as their backup option for remaining listed outside of China if the US followed through on the threat of delisting.
Still, this is the beast from the east, Alibaba. While shares have been heavily discounted in recent years, a specter of their former self remains, as indicated by the stock’s doubling in value in less than three months.
For More Financial News, Click Here.